effect of intravenous acetaminophen on pain manegement

Survey of Intravenous Acetaminophen versus intravenous morphin in acut burn pain management

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201101205588N1

Enrollment

150

Registered

2011-06-30

Start date

2011-02-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: burn. Condition 2: burn. Condition 3: burn. Condition 4: burn. Condition 5: burn. Condition 6: burn. Condition 7: burn. Burn of second degree, body region unspecified Burn of third degree, body region unspecified Burns involving 10-19% of body surface Burns involving 20-29% of body surface Burns involving 30-39% of body surface Burns involving 40-49% of body surface Burns involving 50-59% of body surface

Interventions

Intervention 1: intervention: acetaminophen 15mg/kg Max 1000 mg every 6 hours IV for first day and morphine 0.1 mg/kg every 6 hours IV for second day. Intervention 2: intervation:morphin 0.1 mg/kg ev

Treatment - Drugs

intervention: acetaminophen 15mg/kg Max 1000 mg every 6 hours IV for first day and morphine 0.1 mg/kg every 6 hours IV for second day

intervation:morphin 0.1 mg/kg every 6 hours IV for first day and acetamionophen 15 mg/kg Max 1000mg every 6 hours IV for second day

control: morphin 0.1 mg/kg every 6 hours IV for first day and second day

Eligibility

Sex/Gender

All

Age

15 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:Second or more degree of burn;Burn at least 15% total body surface area AND maximum 50% total body surface area;Hospitalization at least for 2 days;Stable vital signs and ASA I AND ASA II conditions. Exclusion criteria:Drug abuse and addiction;Unstable vital signs; loss of consciousness ;respiratory distress;Pneumothorax or suspicion to that;Bowel obstruction or suspicion to that;Pneumocephalus;Asthma AND COPD AND IHD;Discharged patients by informed consent in less than 2 days of hospitalization;Active chronic liver disease.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain severity. Timepoint: 30 minute and 60 minute after analgesic injection. Method of measurement: visual analoge pain scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSohrabi Karim MD

Tehran University of Medical Sciences

sohrabi@alborz.mui.ac.ir+98 21 4433 4806

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026